Therefore, the use of a potent adjuvant that is able to facilitate the activation of CD8+ cytotoxic T cells specifically to cancer cells of each of the patients is required for the immunotherapy using the cancer cells obtained from the patients. This evidence concerns the gene CD8A and cancer.